Published in PLoS One on July 09, 2015
Understanding the Causes and Implications of Endothelial Metabolic Variation in Cardiovascular Disease through Genome-Scale Metabolic Modeling. Front Cardiovasc Med (2016) 0.75
Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation. Am Heart J (2016) 0.75
Associations of functional alanine-glyoxylate aminotransferase 2 gene variants with atrial fibrillation and ischemic stroke. Sci Rep (2016) 0.75
Ibutilide protects against cardiomyocytes injury via inhibiting endoplasmic reticulum and mitochondrial stress pathways. Heart Vessels (2016) 0.75
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Atrial fibrillation and death after myocardial infarction: a community study. Circulation (2011) 2.63
Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation (2003) 2.30
Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res (2005) 2.24
Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation (2002) 2.22
Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol (2003) 2.19
Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation (2003) 2.12
Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J (2008) 2.03
Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide (1997) 1.85
Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J (2008) 1.85
The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol (2011) 1.58
Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure. Heart (2012) 1.56
The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev (2010) 1.50
Trends in atrial fibrillation complicating acute myocardial infarction. Am J Cardiol (2009) 1.45
Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med (2006) 1.35
Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial fibrillation. Circulation (2013) 1.29
Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol Ther (2013) 1.28
Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci (1998) 1.25
Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant (2008) 1.23
Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators? Arterioscler Thromb Vasc Biol (2012) 1.19
Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol (2004) 1.15
Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol (2013) 1.14
Global epidemiology of atrial fibrillation. Nat Rev Cardiol (2014) 1.12
Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol (2008) 1.10
Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol (2007) 1.07
Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis (2009) 1.07
Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation (2011) 0.93
Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol (2009) 0.92
The impact of rapid atrial pacing on ADMA and endothelial NOS. Int J Cardiol (2010) 0.92
Asymmetrical dimethylarginine level in atrial fibrillation. Acta Cardiol (2008) 0.90
HPLC determination of plasma dimethylarginines: method validation and preliminary clinical application. Clin Chim Acta (2010) 0.85
Variance of DDAH/PRMT/ADMA pathway in atrial fibrillation dogs. Biochem Biophys Res Commun (2008) 0.85
Incidence and prognostic significance of silent atrial fibrillation in acute myocardial infarction. Int J Cardiol (2014) 0.84
Asymmetric dimethylarginine concentration and recurrence of atrial tachyarrythmias after catheter ablation in patients with persistent atrial fibrillation. J Interv Card Electrophysiol (2011) 0.83
High levels of asymmetric dimethylarginine are strongly associated with low HDL in patients with acute myocardial infarction. PLoS One (2013) 0.83
Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. PLoS One (2013) 0.83
Endothelial (dys)function in lone atrial fibrillation. Curr Pharm Des (2015) 0.80
Incidence and prognostic significance of silent atrial fibrillation in acute myocardial infarction. Int J Cardiol (2014) 0.84
Obesity and new-onset atrial fibrillation in acute myocardial infarction: a gender specific risk factor. Int J Cardiol (2014) 0.78
New insights into symptomatic or silent atrial fibrillation complicating acute myocardial infarction. Arch Cardiovasc Dis (2015) 0.76
Prognosis of silent atrial fibrillation after acute myocardial infarction at 1-year follow-up. Heart (2015) 0.76
Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. Am J Cardiol (2016) 0.75